Article Text

SAT0440 New Data on Renal Crisis and Predictive Markers from More Than 3000 Patients
  1. P. Moinzadeh1,
  2. G. Riemekasten2,
  3. G. Fierlbeck3,
  4. J. Henes3,
  5. N. Blank4,
  6. I. Melchers5,
  7. U. Mueller-Ladner6,
  8. A. Kreuter7,
  9. L. Susok8,
  10. C. Guenther9,
  11. G. Zeidler10,
  12. C. Pfeiffer11,
  13. M. Worm2,
  14. E. Aberer12,
  15. E. Genth13,
  16. J.H. Distler14,
  17. R. Hein15,
  18. M. Sárdy16,
  19. H. Mensing17,
  20. I. Koetter18,
  21. C. Sunderkoetter19,
  22. M. Hellmich20,
  23. T. Krieg1,
  24. N. Hunzelmann1
  1. 1University Hospital, Cologne
  2. 2Charité University Hospital, Berlin
  3. 3University Hospital, Tübingen
  4. 4University Hospital, Heidelberg
  5. 5University Hospital, Freiburg
  6. 6Kerckhoff Clinic, Bad Nauheim
  7. 7HELIOS Clinic, Oberhausen
  8. 8University Hospital, Bochum
  9. 9University Hospital, Dresden
  10. 10Johanniter-Hospital, Treuenbrietzen
  11. 11University Hospital, Ulm, Germany
  12. 12University Hospital, Gaz, Austria
  13. 13Clinic of Rheumatology, Aachen
  14. 14University Hospital, Erlangen
  15. 15TUM
  16. 16Ludwig Maximilian University, Munich
  17. 17Dermatological Clinic
  18. 18Asklepios Clinic Altona, Hamburg
  19. 19University Hospital, Muenster
  20. 20IMSIE, Cologne, Germany


Background To improve detection and follow-up of patients with systemic sclerosis, the German Network for Systemic Scleroderma (DNSS) was founded 2003 and comprise rheumatologists, dermatologists, pulmonologists and nephrologists from more than 40 medical centers. Renal crisis is rare but still a medical emergency in patients with SSc.

Objectives Up to date, more than 3000 patients have been grouped into four descriptive disease subsets, i.e. limited cutaneous disease (lcSSc), diffuse cutaneous disease (dcSSc), overlap-syndrome and undifferentiated connective tissue disease (UCTD) with scleroderma features.

Methods In this analysis, we have focused on renal crisis within the three main subsets, e.g. lcSSc, dcSSc and overlap-syndromes to identify baseline aspects, which are predictive for future SSc associated renal crisis.

Results Recent analyses of up to now 3180 patients revealed that 56% of patients suffer from limited SSc (lcSSc), 34% from diffuse SSc (dcSSc) and 11% of patients were diagnosed with an overlap-syndrome. Eighteen patients developed a renal crisis (1.4%, 18/3180), while 10% (315/3180) were classified with kidney involvement and 8% (257/3180) with proteinuria. Of these, 66.7% (12/18) were diagnosed with the diffuse form of SSc, while just 27.8% (5/18) were diagnosed with lcSSc and 5.6% (1/18) with SSc-overlap syndromes.

Predictive factors for renal crisis in our patient cohort included the diffuse form of SSc (odds ratio (OR) 4.6, p=0.005, 95%>confidence interval (CI) 1.6-13.5), a modified Rodnan skin score (mRSS) of more than 15 (OR 4.7; p=0.002, 95%>CI 1.7-13), positive anti-RNA polymerase (RNAP) autoantibodies (OR 24.6, p<0.0001, 95%>CI 6.1-99.5), tendon friction rubs (OR 5.4, p=0.004, 95%>CI 1.7-16.9), hypertension (OR 6.1, p<0.0001, 95%>CI 2.3-16.5), proteinuria (OR 11.8, p<0.0001, 95%>CI 4.3-32.1) and elevated CK-levels (OR 5.1, p=0.01, 95%>CI 1.4-18.9). Interestingly, positive anti-topoisomerase autoantibodies did not predict a higher risk for renal crisis. Patients diagnosed with renal crisis were significantly more frequent on ACE-inhibitors (61.1%, 11/18, p=0.001). Of these, 5 patients also suffered from proteinuria and 7 patients from hypertension. Patients on systemic glucocorticoids had also an increased risk to develop a renal crisis (OR 5.1, p=0.002, 95%>CI 1.8-14.3), independent of the dosage (> or <7.5mg/day).

Conclusions Renal crisis has become a rare complication in SSc. The highest risk was associated with the detection of RNAP antibodies, followed by proteinuria, hypertension, tendon friction rubs, elevated CK-levels and a modified Rodnan skin Score above 15. Close monitoring of patients at high risk for SSc associated renal crisis is mandatory.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.